PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1458408
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1458408
Particle Therapy Market Assessment, By Type, By System, By Product & Service, By Cancer Type, By Application, By Region, Opportunities and Forecast, 2017-2031F
Global particle therapy market is projected to witness a CAGR of 8.2% during the forecast period 2024-2031, growing from USD 651.4 million in 2023 to USD 1223.67 million in 2031F.
The growing prevalence of cancer in various regions across the globe, rising investments towards the improvement of healthcare infrastructure, increasing research and development activities, and technological advancements are some of the major factors driving the market growth. The introduction of technologically advanced products and systems is another crucial factor supporting market growth.
For instance, in January 2024, OncoRay launched the world's first research prototype for whole-body MRI-guided proton therapy system. The prototype is designed for MRI-tracking moving tumors during proton therapy in real time. With the help of MRI, the visualization of surrounding healthy tissue and moving tumors with soft-tissue contrast becomes easier. The MRI will also be able to detect all anatomical changes between treatment sessions. The prototype combines a whole-body MRI scanner with a horizontal proton therapy beamline. The geometry of the prototype enables innovative patient positioning approaches such as treatment in both upright and lying positions.
One of the major global particle therapy market trends includes growing preference for proton therapy for treatment of cancer. This increased preference can be attributed to the targeted nature of the particle therapy that allows it to cause less damage to the surrounding tissues.
The growing efforts by various leading market players towards delivering technologically advanced solutions are also bolstering the market expansion.
For instance, in 2023, Hitachi, Ltd. Delivered a proton therapy system to National Cancer Centre Singapore (NCCS), marking their first proton therapy system to initiate treatment in Southeast Asia.
Rising Prevalence of Cancer Aids Market Expansion
The utilization of particle therapy for treating tumors present in the thoracic region, prostate, central nervous system, and head-and-neck is growing due to their increased prevalence. Particle therapy can also be effective for treating radio-resistant tumors and re-irradiation. The therapy is especially advantageous for radio-resistant tumors including chordomas and chondrosarcomas of the skull base owing to their location near the critical structures such as cranial nerves and brainstem. The biological and physical properties of particle therapy are effective in reducing the acute toxicities that are radiation largely induced. Particle therapy also effectively reduces integral dose.
Proton therapy is increasingly being used for treating patients with tumors near the brain and benign tumors as well as for treating patients who have undergone treatment but still have recurrent brain tumors. As per the National Brain Tumor Society, around one million individuals are living with a brain tumor in America. They also estimated that in 2023 approximately 94,390 individuals were expected to receive a primary brain tumor diagnosis.
Increasing Research and Development Activities Supports Global Particle Therapy Market Growth
The increased adoption of particle therapy for treating different cancer types is bolstering the investments in research and development activities. A wide range of trials have already established the benefits offered by particle therapy in select clinical situations. Further research activities are expected to enhance treatment planning, beam delivery, and image guidance. Various research institutions are also initiating proton therapy partnerships, for instance, in June 2023, PARTICLE (Particle Therapy Interuniversity Center Leuven) and IBA, one of the leading providers of proton therapy solutions for treating cancer initiated a research partnership for developing ConformalFLASH. For facilitating preclinical research on FLASH therapy in the clinical proton therapy system of PARTICLE, IBA will enable FLASH configuration. The researchers from UCLouvain, UZ Leuven, and KU Leuven will be performing preclinical experiments using IBA's Proteus ONE to evaluate the FLASH effect on normal tissue toxicity.
North America Expected to Witness Significant Growth
The growth of the North America particle therapy market can be attributed to the easy availability of innovative medical technologies in the region and presence of a well-established healthcare infrastructure. The ongoing research activities related to particle therapy in various medical schools and research institutes and centers is further supporting the market expansion in North America. Due to the easy accessibility to coverage and health insurance, receiving novel treatments is easier. The presence of technologically advanced devices for diagnosing various diseases and disorders, growing prevalence of cancer, and introduction of advanced and innovative technologies by the leading manufacturers are also boosting the market growth. According to the estimates of the American Cancer Society, approximately 609,820 deaths related to cancer and 1,958,310 new cancer cases were estimated to occur in the U.S. in 2023. In addition, the opening of proton therapy centers in the region is also supporting the market expansion. In 2023, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Nationwide Children's Hospital opened a new proton therapy center. The highly targeted form of radiation therapy is offered in Central Ohio for treating tumors that cannot be removed via surgery.
The Dominance of Proton Therapy
The segment growth can be attributed to the high rate of adoption of proton therapy for treating several types of cancer including breast cancer, pediatric cancer, and brain cancer. Proton therapy is increasingly being used in various stages of treatment of breast cancer owing to high linear energy distribution and effective deep dose distribution of charged particles, leading to the formation of DNA lesions. The increasing research and development activities are further supporting the expansion of the segment.
For instance, a team of researchers from Paul Scherrer Institute in Switzerland in collaboration with IBA Dosimetry is testing if a software-based solution having the ability to recalculate the delivered dose from the treatment log files can offer a better solution. The research team also worked with Varian to extract the treatment log files from their ProBeam machine for proton therapy. These files were then converted into the standard DiCOM format that is used by the IBA Dosimetry's myQA iON platform for patient-specific quality analysis.
Pediatric Cancer Anticipated to Boost Global Particle Therapy Market Demand
The increasing prevalence of pediatric cancer owing to various factors including the presence of an immature immune system and genetic predisposition is providing lucrative growth opportunities to the market growth. According to the National Cancer Institute, it was estimated that in 2023 approximately 15,190 children and adolescents aging from 0 to 19 will receive a diagnosis for cancer and approximately 1,590 will die from the same in the United States. About 8-10% of cancer cases in children are caused due to inherited pathogenic variant in cancer predisposition gene. Children that inherit the different variants associated with familial syndromes such as Noonan syndrome, Beckwith-Wiedemann syndrome, von Hippel-Lindau syndrome, Fanconi anemia, and Fraumeni syndrome also have a substantial risk of developing cancer in childhood.
As the protons can be controlled in a precise manner, proton therapy is preferred for treating pediatric tumors that are located near growing tissues in the eyes, mouth, ears, brain, and spinal cord.
Future Market Scenario (2024-2031F)
According to the global particle therapy market analysis, while the clinical and physical benefits of particle therapy are well recognized, further research and development activities are required to assess the effectiveness and safety of these therapies.
For instance, a team of researchers from Mayo Clinic, Minnesota, U.S. are conducting an interventional study to gather information on the effectiveness and safety of proton radiation therapy in subjects who are experiencing ventricular tachycardia despite undergoing a previous catheter ablation and treatment with an implantable cardioverter defibrillator for reducing the number of ventricular tachycardia episodes. The subjects of the study will be followed at one and two weeks and one, three-, six-, twelve- and twenty-four-month intervals. The study is expected to conclude in March 2025. The development of novel proton radiation therapy approaches is expected to be of substantial value in providing alternative therapies to catheter-based ablation and drug therapy.
Key Players Landscape and Outlook
The market is expected to witness significant growth over the forecast period owing to rising research and development activities and collaborations between leading market players and research and care institutions.
For instance, Hitachi Ltd. is collaborating with the University of Texas MD Anderson Cancer Center on research for a randomized clinical trial to compare the side effects and outcomes of Intensity Modulated Radiation Therapy (IMRT) versus Intensity Modulated Proton Therapy (IMPT) for treating oropharyngeal cancer of the neck and head. The company's proton beam therapy cancer treatment solutions require fewer hospital visits, have lower radiation exposure, and are less invasive.
Table of Contents
1.Research Methodology
2.Project Scope & Definitions
3.Executive Summary
4.Global Particle Therapy Market Outlook, 2017-2031F
- 4.1.Market Size & Forecast
- 4.1.1. By Value
- 4.2.By Type
- 4.2.1. Heavy Ion Therapy
- 4.2.2. Proton Therapy
- 4.3.By System
- 4.3.1. Single-Room Systems
- 4.3.2. Multi-Room Systems
- 4.4.By Product & Service
- 4.4.1. Products
- 4.4.1.1.Synchrotrons
- 4.4.1.2.Synchrocyclotrons
- 4.4.1.3.Cyclotrons
- 4.4.2.Services
- 4.4.1. Products
- 4.5.By Cancer Type
- 4.5.1. Prostate Cancer
- 4.5.2. Pediatric Cancer
- 4.5.3. Breast Cancer
- 4.5.4. Lung Cancer
- 4.5.5. Brain and Spinal Cord Cancer
- 4.5.6. Others
- 4.6.By Application
- 4.6.1. Research Applications
- 4.6.2. Treatment Applications
- 4.7.By Region
- 4.7.1. North America
- 4.7.2. South America
- 4.7.3. Europe
- 4.7.4. Asia-Pacific
- 4.7.5. Middle East & Africa
- 4.8.By Company Market Share (%), 2023
5.Global Particle Therapy Market Outlook, By Region, 2017-2031F
- 5.1.North America*
- 5.1.1. Market Size & Forecast
- 5.1.1.1.By Value
- 5.1.2.By Type
- 5.1.2.1.Heavy Ion Therapy
- 5.1.2.2.Proton Therapy
- 5.1.3. By System
- 5.1.3.1.Single-Room Systems
- 5.1.3.2.Multi-Room Systems
- 5.1.4. By Product & Service
- 5.1.4.1.Products
- 5.1.4.1.1.Synchrotrons
- 5.1.4.1.2.Synchrocyclotrons
- 5.1.4.1.3.Cyclotrons
- 5.1.4.2.Services
- 5.1.5. By Cancer Type
- 5.1.5.1.Prostate Cancer
- 5.1.5.2.Pediatric Cancer
- 5.1.5.3.Breast Cancer
- 5.1.5.4.Lung Cancer
- 5.1.5.5.Brain and Spinal Cord Cancer
- 5.1.5.6.Others
- 5.1.6. By Application
- 5.1.6.1.Research Applications
- 5.1.6.2.Treatment Applications
- 5.1.7. United States*
- 5.1.7.1.Market Size & Forecast
- 5.1.7.1.1.By Value
- 5.1.7.2.By Type
- 5.1.7.2.1.Heavy Ion Therapy
- 5.1.7.2.2.Proton Therapy
- 5.1.7.3.By System
- 5.1.7.3.1.Single-Room Systems
- 5.1.7.3.2.Multi-Room Systems
- 5.1.7.4.By Product & Service
- 5.1.7.4.1.Products
- 5.1.7.4.1.1.Synchrotrons
- 5.1.7.4.1.2.Synchrocyclotrons
- 5.1.7.4.1.3.Cyclotrons
- 5.1.7.4.2.Services
- 5.1.7.5.By Cancer Type
- 5.1.7.5.1.Prostate Cancer
- 5.1.7.5.2.Pediatric Cancer
- 5.1.7.5.3.Breast Cancer
- 5.1.7.5.4.Lung Cancer
- 5.1.7.5.5.Brain and Spinal Cord Cancer
- 5.1.7.5.6.Others
- 5.1.7.6.By Application
- 5.1.7.6.1.Research Applications
- 5.1.7.6.2.Treatment Applications
- 5.1.8. Canada
- 5.1.9. Mexico
- 5.1.1. Market Size & Forecast
All segments will be provided for all regions and countries covered
- 5.2.Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
- 5.3.Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
- 5.4.South America
- 5.4.1. Brazil
- 5.4.2. Argentina
- 5.5.Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. U.A.E.
- 5.5.3. South Africa
6.Market Mapping, 2023
- 6.1.By Type
- 6.2.By System
- 6.3.By Product & Service
- 6.4.By Cancer Type
- 6.5.By Application
- 6.6.By Region
7.Macro Environment and Industry Structure
- 7.1.Supply Demand Analysis
- 7.2.Import Export Analysis
- 7.3.Value Chain Analysis
- 7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry
8.Market Dynamics
- 8.1.Growth Drivers
- 8.2.Growth Inhibitors (Challenges and Restraints)
9.Regulatory Framework and Innovation
- 9.1.Patent Landscape
- 9.2.Regulatory Approvals
- 9.3.Innovations/Emerging Technologies
10.Key Players Landscape
- 10.1.Competition Matrix of Top Five Market Leaders
- 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
- 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
- 10.4.SWOT Analysis (For Five Market Players)
- 10.5.Patent Analysis (If Applicable)
11.Pricing Analysis
12.Case Studies
13.Key Players Outlook
- 13.1.Hitachi Ltd.
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
- 13.2.Varian Medical Systems, Inc.
- 13.3.IBA Worldwide
- 13.4.ProTom International, Inc.
- 13.5.Sumitomo Heavy Industries, Ltd.
- 13.6.Provision Healthcare, LLC
- 13.7.Mevion Medical Systems, Inc.
- 13.8.Optivus Proton Therapy, Inc.
- 13.9.Danfysik A/S
- 13.10.Toshiba Medical Systems Corporation
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
14.Strategic Recommendations
15.About Us & Disclaimer
List of Tables
- Table 1. Pricing Analysis of Products from Key Players
- Table 2. Competition Matrix of Top 5 Market Leaders
- Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1.Global Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 2.Global Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 3.Global Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 4.Global Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 5.Global Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 6.Global Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 7.Global Particle Therapy Market Share (%), By Region, 2017-2031F
- Figure 8.North America Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 9.North America Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 10.North America Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 11.North America Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 12.North America Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 13.North America Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 14.North America Particle Therapy Market Share (%), By Country, 2017-2031F
- Figure 15.United States Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 16.United States Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 17.United States Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 18.United States Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 19.United States Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 20.United States Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 21.Canada Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 22.Canada Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 23.Canada Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 24.Canada Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 25.Canada Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 26.Canada Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 27.Mexico Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 28.Mexico Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 29.Mexico Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 30.Mexico Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 31.Mexico Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 32.Mexico Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 33.Europe Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 34.Europe Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 35.Europe Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 36.Europe Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 37.Europe Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 38.Europe Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 39.Europe Particle Therapy Market Share (%), By Country, 2017-2031F
- Figure 40.Germany Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 41.Germany Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 42.Germany Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 43.Germany Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 44.Germany Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 45.Germany Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 46.France Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 47.France Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 48.France Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 49.France Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 50.France Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 51.France Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 52.Italy Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 53.Italy Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 54.Italy Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 55.Italy Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 56.Italy Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 57.Italy Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 58.United Kingdom Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 59.United Kingdom Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 60.United Kingdom Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 61.United Kingdom Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 62.United Kingdom Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 63.United Kingdom Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 64.Russia Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 65.Russia Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 66.Russia Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 67.Russia Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 68.Russia Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 69.Russia Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 70.Netherlands Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 71.Netherlands Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 72.Netherlands Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 73.Netherlands Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 74.Netherlands Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 75.Netherlands Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 76.Spain Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 77.Spain Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 78.Spain Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 79.Spain Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 80.Spain Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 81.Spain Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 82.Turkey Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 83.Turkey Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 84.Turkey Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 85.Turkey Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 86.Turkey Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 87.Turkey Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 88.Poland Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 89.Poland Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 90.Poland Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 91.Poland Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 92.Poland Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 93.Poland Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 94.South America Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 95.South America Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 96.South America Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 97.South America Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 98.South America Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 99.South America Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 100.South America Particle Therapy Market Share (%), By Country, 2017-2031F
- Figure 101.Brazil Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 102.Brazil Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 103.Brazil Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 104.Brazil Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 105.Brazil Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 106.Brazil Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 107.Argentina Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 108.Argentina Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 109.Argentina Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 110.Argentina Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 111.Argentina Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 112.Argentina Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 113.Asia-Pacific Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 114.Asia-Pacific Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 115.Asia-Pacific Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 116.Asia-Pacific Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 117.Asia-Pacific Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 118.Asia-Pacific Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 119.Asia-Pacific Particle Therapy Market Share (%), By Country, 2017-2031F
- Figure 120.India Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 121.India Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 122.India Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 123.India Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 124.India Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 125.India Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 126.China Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 127.China Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 128.China Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 129.China Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 130.China Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 131.China Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 132.Japan Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 133.Japan Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 134.Japan Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 135.Japan Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 136.Japan Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 137.Japan Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 138.Australia Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 139.Australia Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 140.Australia Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 141.Australia Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 142.Australia Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 143.Australia Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 144.Vietnam Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 145.Vietnam Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 146.Vietnam Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 147.Vietnam Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 148.Vietnam Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 149.Vietnam Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 150.South Korea Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 151.South Korea Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 152.South Korea Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 153.South Korea Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 154.South Korea Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 155.South Korea Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 156.Indonesia Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 157.Indonesia Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 158.Indonesia Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 159.Indonesia Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 160.Indonesia Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 161.Indonesia Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 162.Philippines Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 163.Philippines Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 164.Philippines Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 165.Philippines Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 166.Philippines Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 167.Philippines Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 168.Middle East & Africa Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 169.Middle East & Africa Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 170.Middle East & Africa Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 171.Middle East & Africa Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 172.Middle East & Africa Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 173.Middle East & Africa Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 174.Middle East & Africa Particle Therapy Market Share (%), By Country, 2017-2031F
- Figure 175.Saudi Arabia Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 176.Saudi Arabia Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 177.Saudi Arabia Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 178.Saudi Arabia Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 179.Saudi Arabia Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 180.Saudi Arabia Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 181.UAE Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 182.UAE Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 183.UAE Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 184.UAE Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 185.UAE Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 186.UAE Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 187.South Africa Particle Therapy Market, By Value, In USD Million, 2017-2031F
- Figure 188.South Africa Particle Therapy Market Share (%), By Type, 2017-2031F
- Figure 189.South Africa Particle Therapy Market Share (%), By System, 2017-2031F
- Figure 190.South Africa Particle Therapy Market Share (%), By Product & Service, 2017-2031F
- Figure 191.South Africa Particle Therapy Market Share (%), By Cancer Type, 2017-2031F
- Figure 192.South Africa Particle Therapy Market Share (%), By Application, 2017-2031F
- Figure 193.By Type Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 194.By System Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 195.By Product & Service Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 196.By Cancer Type Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 197.By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 198.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
